Compare Stocks: RAPP, PCVX, RYTM, and IBRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$7.45 +9.1%	$7.70	$1.95 ▼ $12.43	$7.15B	0.01	9.23 million shs	10.98 million shs
PCVX Vaxcyte	$55.96 +5.6%	$53.11	$29.08 ▼ $65.00	$7.65B	1.22	1.02 million shs	817,948 shs
RAPP Rapport Therapeutics	$42.78 +4.5%	$39.28	$13.62 ▼ $44.28	$1.96B	0.94	365,907 shs	216,870 shs
RYTM Rhythm Pharmaceuticals	$105.74 -0.7%	$100.34	$74.50 ▼ $122.20	$7.30B	1.88	608,484 shs	534,585 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	-2.01%	-9.05%	-22.12%	-3.80%	+168.90%
PCVX Vaxcyte	-2.97%	-5.39%	-8.21%	-7.44%	+52.77%
RAPP Rapport Therapeutics	-2.43%	-0.94%	+1.36%	+23.57%	+165.50%
RYTM Rhythm Pharmaceuticals	-1.40%	+2.46%	-3.19%	+30.94%	+24.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$7.45 +9.1%	$7.70	$1.95 ▼ $12.43	$7.15B	0.01	9.23 million shs	10.98 million shs
PCVX Vaxcyte	$55.96 +5.6%	$53.11	$29.08 ▼ $65.00	$7.65B	1.22	1.02 million shs	817,948 shs
RAPP Rapport Therapeutics	$42.78 +4.5%	$39.28	$13.62 ▼ $44.28	$1.96B	0.94	365,907 shs	216,870 shs
RYTM Rhythm Pharmaceuticals	$105.74 -0.7%	$100.34	$74.50 ▼ $122.20	$7.30B	1.88	608,484 shs	534,585 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	-2.01%	-9.05%	-22.12%	-3.80%	+168.90%
PCVX Vaxcyte	-2.97%	-5.39%	-8.21%	-7.44%	+52.77%
RAPP Rapport Therapeutics	-2.43%	-0.94%	+1.36%	+23.57%	+165.50%
RYTM Rhythm Pharmaceuticals	-1.40%	+2.46%	-3.19%	+30.94%	+24.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBRX ImmunityBio	2.71	Moderate Buy	$14.20	90.60% Upside
PCVX Vaxcyte	2.44	Hold	$86.00	53.68% Upside
RAPP Rapport Therapeutics	2.92	Moderate Buy	$57.86	35.24% Upside
RYTM Rhythm Pharmaceuticals	2.78	Moderate Buy	$138.73	31.20% Upside

Current Analyst Ratings Breakdown

Latest RAPP, PCVX, RYTM, and IBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2026	RAPP Rapport Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
7/27/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$145.00
7/17/2026	RAPP Rapport Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	RYTM Rhythm Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	RAPP Rapport Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
7/14/2026	PCVX Vaxcyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/10/2026	IBRX ImmunityBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	RYTM Rhythm Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$137.00 ➝ $141.00
7/6/2026	PCVX Vaxcyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	RAPP Rapport Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$52.00
6/17/2026	RYTM Rhythm Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBRX ImmunityBio	$113.29M	68.87	N/A	N/A	($0.51) per share	-14.61
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$10.17 per share	N/A
RYTM Rhythm Pharmaceuticals	$189.76M	38.19	N/A	N/A	$2.08 per share	50.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBRX ImmunityBio	-$351.40M	-$0.85	N/A	N/A	N/A	-606.15%	N/A	-59.53%	8/4/2026 (Estimated)
PCVX Vaxcyte	-$766.63M	-$6.88	N/A	N/A	N/A	N/A	-32.51%	-29.51%	8/5/2026 (Estimated)
RAPP Rapport Therapeutics	-$111.48M	-$2.60	N/A	N/A	N/A	N/A	-24.78%	-23.44%	8/6/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.13	N/A	N/A	N/A	-93.33%	-203.25%	-44.99%	8/4/2026 (Estimated)

Latest RAPP, PCVX, RYTM, and IBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	RAPP Rapport Therapeutics	-$0.93	N/A	N/A	N/A	$20.00 million	N/A
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.0556	N/A	N/A	N/A	$12.50 million	N/A
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.09	N/A	N/A	N/A	$49.70 million	N/A
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.82	N/A	N/A	N/A	$67.66 million	N/A
5/7/2026	Q1 2026	IBRX ImmunityBio	-$0.08	-$0.62	-$0.54	-$0.62	$43.07 million	$44.21 million
5/7/2026	Q1 2026	RAPP Rapport Therapeutics	-$0.56	-$0.42	+$0.14	-$0.42	$7.50 million	$20.00 million
5/6/2026	Q1 2026	PCVX Vaxcyte	-$1.7411	-$2.30	-$0.5589	-$2.30	$12.50 million	N/A
5/5/2026	Q1 2026	RYTM Rhythm Pharmaceuticals	-$0.86	-$0.83	+$0.03	-$0.83	$55.78 million	$60.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBRX ImmunityBio	N/A	6.67	6.66
PCVX Vaxcyte	N/A	7.49	7.49
RAPP Rapport Therapeutics	N/A	27.08	27.08
RYTM Rhythm Pharmaceuticals	N/A	4.17	3.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBRX ImmunityBio	8.58%
PCVX Vaxcyte	96.78%
RAPP Rapport Therapeutics	N/A
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
IBRX ImmunityBio	66.10%
PCVX Vaxcyte	3.30%
RAPP Rapport Therapeutics	12.48%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBRX ImmunityBio	590	1.05 billion	355.05 million	Optionable
PCVX Vaxcyte	160	144.40 million	139.63 million	Optionable
RAPP Rapport Therapeutics	N/A	47.83 million	41.86 million	N/A
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable

RAPP, PCVX, RYTM, and IBRX Headlines

Recent News About These Companies

Rhythm Pharmaceuticals Inc.

4 hours ago | marketwatch.com

Renaissance Technologies LLC Lowers Stake in Rhythm Pharmaceuticals, Inc. $RYTM

July 30 at 5:04 AM | marketbeat.com

Rhythm Pharmaceuticals, Inc. $RYTM Position Raised by ADAR1 Capital Management LLC

July 29 at 3:03 AM | marketbeat.com

JPMorgan Chase & Co. Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)

July 29 at 1:42 AM | americanbankingnews.com

Could Anticipated Q2 Earnings Beat Amid Weaker Profitability Reframe Rhythm Pharmaceuticals’ Growth Story (RYTM)?

July 28 at 12:11 AM | uk.finance.yahoo.com

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

July 28 at 11:06 AM | zacks.com

Rhythm Pharmaceuticals (RYTM) Projected to Announce Earnings on Tuesday

July 28 at 8:40 AM | marketbeat.com

Exome Asset Management LLC Takes $3.53 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM

July 28 at 6:23 AM | marketbeat.com

Hsbc Holdings PLC Invests $1.23 Million in Rhythm Pharmaceuticals, Inc. $RYTM

July 28 at 4:07 AM | marketbeat.com

Castleark Management LLC Sells 12,200 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

July 28 at 3:36 AM | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated by Analysts at JPMorgan Chase & Co.

July 27 at 8:05 AM | marketbeat.com

Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by Orbimed Advisors LLC

July 27 at 6:23 AM | marketbeat.com

Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by SummitTX Capital L.P.

July 27 at 6:16 AM | marketbeat.com

First Light Asset Management LLC Sells 208,663 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

July 27 at 4:24 AM | marketbeat.com

Granahan Investment Management LLC Increases Stock Position in Rhythm Pharmaceuticals, Inc. $RYTM

July 25, 2026 | marketbeat.com

Siren L.L.C. Grows Holdings in Rhythm Pharmaceuticals, Inc. $RYTM

July 24, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Brokerages

July 22, 2026 | americanbankingnews.com

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

July 21, 2026 | prnewswire.com

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

July 21, 2026 | markets.businessinsider.com

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

July 21, 2026 | globenewswire.com

Rhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by WCM Investment Management LLC

July 21, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP, PCVX, RYTM, and IBRX Company Descriptions

ImmunityBio NASDAQ:IBRX

$7.45 +0.62 (+9.08%)

Closing price 04:00 PM Eastern

Extended Trading

$7.54 +0.09 (+1.14%)

As of 07:59 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Vaxcyte NASDAQ:PCVX

$55.96 +2.98 (+5.62%)

Closing price 04:00 PM Eastern

Extended Trading

$55.95 -0.01 (-0.02%)

As of 07:34 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Rapport Therapeutics NASDAQ:RAPP

$42.78 +1.84 (+4.49%)

Closing price 04:00 PM Eastern

Extended Trading

$43.66 +0.88 (+2.07%)

As of 07:49 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Rhythm Pharmaceuticals NASDAQ:RYTM

$105.74 -0.79 (-0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$105.76 +0.03 (+0.02%)

As of 07:34 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RAPP, PCVX, RYTM, and IBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RAPP, PCVX, RYTM, and IBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RAPP, PCVX, RYTM, and IBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP, PCVX, RYTM, and IBRX Company Descriptions

ImmunityBio NASDAQ:IBRX

Vaxcyte NASDAQ:PCVX

Rapport Therapeutics NASDAQ:RAPP

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RAPP, PCVX, RYTM, and IBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RAPP, PCVX, RYTM, and IBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RAPP, PCVX, RYTM, and IBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP, PCVX, RYTM, and IBRX Company Descriptions

ImmunityBio NASDAQ:IBRX

Vaxcyte NASDAQ:PCVX

Rapport Therapeutics NASDAQ:RAPP

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools